Yichun

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.

Breast cancer is the most common cancer among women worldwide and carries a high risk of death. About 5% to 10% of breast cancers are inherited, mostly linked to mutations in BRCA1, BRCA2, and PALB2 genes. Women with these mutations have a high lifetime risk of breast cancer and a significantly increased risk of developing cancer in the opposite breast after an initial diagnosis. While removal of the opposite breast is often recommended to reduce this risk, many women decline due to concerns about surgery and its effects on body image and sexuality. This trial compares two approaches for women with BRCA1, BRCA2, or PALB2 mutations who have early-stage breast cancer. One group receives standard local treatment without radiation to the opposite breast, while the other group receives standard treatment plus radiation to the opposite breast. Radiation is delivered daily, five days a week, for 5 to 6 weeks at a total dose of 45-50 Gy. The goal is to see if radiation can reduce the risk of cancer developing in the opposite breast, potentially offering an alternative to surgery. Participants will be followed for up to 10 years to monitor for development of cancer in the opposite breast, overall survival, local recurrences, distant metastasis, and any side effects from radiation. Follow-up visits occur every 3 to 6 months initially, including imaging and clinical evaluations. Safety is closely monitored, especially during the first 3 months after radiation starts, with long-term effects tracked throughout the study. The study aims to provide important information about the potential role of radiation to prevent new breast cancers in this high-risk group.